Introduction/Overview
Cardiovascular disease is the leading cause of death and disability worldwide, with diseases such as heart failure and arrhythmia posing a serious threat to human health. In the process of exploring new therapeutic drugs, natural products have always been an important treasure trove for drug discovery due to their structural diversity and rich biological activity. Cyclovirobuxine D (CVB-D), a steroid alkaloid isolated from traditional Chinese medicine boxwood, is increasingly becoming a star molecule in the field of cardiovascular pharmacology research. Its CAS number is 860-79-7, which is the traditional Chinese medicine boxwood（Buxus microphylla）One of the main active ingredients that exert pharmacological effects. Early research has revealed that it has clear pharmacological activities such as cardiotonic and antiarrhythmic effects, and has been used as a drug (such as Huanwei Huangyanxing D tablets) in clinical practice to treat diseases such as arrhythmia and angina pectoris. In recent years, with the rapid development of molecular pharmacology and cell biology techniques, research on CVB-D has surpassed the traditional cardiovascular category. Its new activities such as anti-tumor and autophagy induction have been continuously discovered, and the mechanism of action has been increasingly studied, involving the regulation of multiple targets such as the Akt/mTOR signaling pathway, cell cycle, and mitochondrial apoptosis pathway. This article aims to systematically review the chemical structure, plant origin, pharmacological activity, molecular mechanism of action, pharmacological characteristics, and clinical application prospects of CVB-D, in order to provide comprehensive scientific references for the in-depth research and development of this natural product.
Chemical structure and physicochemical properties
Cyclovirobuxine D is a steroid alkaloid with a complex four ring skeleton. Its molecular formula is C26H46N2O and its molecular weight is 402.6670. Its core structure is cyclopregnane, which is connected to amino functional groups at positions C-3 and C-20, respectively. This is the structural basis of its alkaloid properties and also has a decisive impact on its pharmacological activity and physicochemical properties.
From the analysis of physical and chemical properties, the calculated LogP of CVB-D is about 4.9954, indicating that the compound has high lipophilicity. Its topological polar surface area (TPSA) is 44.29 Å ², which is relatively small. These parameters collectively determine the distribution characteristics of CVB-D in organisms: its water solubility is low (about 0.1336 mg/mL), but it is easy to penetrate the lipid bilayer. It is worth noting that its blood-brain barrier (BBB) penetration is predicted to be "high", indicating that it may have central nervous system activity or potential risk of central side effects, which needs attention in drug development. In early safety screening, CVB-D did not show significant hERG potassium channel inhibitory activity (predicted as' no '), which to some extent reduces its cardiotoxicity risk of inducing acquired long QT syndrome and apical torsion transition ventricular tachycardia, providing a favorable structural basis for its safety as an antiarrhythmic drug. In addition, the Ames test predicted a value of 0.0, indicating that it may not have direct genetic toxicity.
Plant sources and extraction methods
Huangyangtao mainly comes from the Buxaceae family and the boxwood genus（Buxus）Plants, including small leaved boxwood（Buxus microphylla）It is its main and traditional plant source. In addition, the Jin ripe boxwood of the same genus（Buxus sempervirens）Plants also contain CVB-D and its structural analogues. As an evergreen shrub, boxwood has long been recorded in traditional Chinese medicine for the treatment of cardiovascular and cerebrovascular diseases, malaria, skin diseases, etc.
Extracting and purifying CVB-D from plant materials is a multi-step process that typically combines traditional solvent extraction methods with modern chromatographic separation techniques. The standard procedure is as follows:
1. Raw material pretreatment Crush dry boxwood or leaves to increase the extraction surface area.
2. Solvent extraction Acidic aqueous solutions (such as dilute hydrochloric acid, dilute acetic acid) or alcohol water mixed solvents (such as ethanol water) are commonly used for leaching or reflux extraction. Acidic conditions facilitate the conversion of alkaloid components in plants into water-soluble salt forms for dissolution.
3. Alkalization and extraction Alkalize the acidic extraction solution (such as adjusting the pH to alkaline with ammonia or sodium hydroxide), allowing the alkaloids to precipitate freely, and then repeatedly extract with organic solvents (such as chloroform, dichloromethane, or ethyl acetate) to enrich the total alkaloids.
4. Separation and Purification Separate the crude total alkaloids obtained by methods such as silica gel column chromatography, alumina column chromatography, high-performance liquid chromatography (HPLC), or preparative thin-layer chromatography. Due to CVB-D being one of the main active ingredients and having a relatively high content in the total base, it is often used as a target compound for separation and purification. By comparing its physical and chemical properties (such as melting point, specific rotation) and spectral data (such as mass spectrometry MS, nuclear magnetic resonance NMR) with the reference substance, its structure can be confirmed.
In recent years, new technologies such as ultrasound assisted extraction and microwave-assisted extraction have also been applied in the extraction process to improve extraction efficiency and save time.
Pharmacological activity research
The pharmacological activity research of Huangyang alkaloid shows a trend of expanding from the cardiovascular system to multiple systems, and its core activities can be summarized as follows:
1. Cardiovascular system activity
This is the field where CVB-D was first recognized and researched, and it is also the cornerstone of its clinical application.
* Antiarrhythmic treatment CVB-D has shown good antagonistic effects on various experimental arrhythmia models, such as aconitine, barium chloride, adrenaline, and coronary artery ligation induced arrhythmia. Its characteristic of action is similar to class III antiarrhythmic drugs, mainly by prolonging the action potential duration (APD) and effective refractory period (ERP) of myocardial cells, interrupting the reentry loop, and thereby inhibiting the occurrence of arrhythmia.
* Positive inotropic effect CVB-D can enhance myocardial contractility, increase cardiac output, and does not significantly increase myocardial oxygen consumption, which makes it therapeutic for heart failure.
* Cardioprotective effect In myocardial ischemia/reperfusion injury and myocardial infarction models, CVB-D can alleviate myocardial cell damage and reduce infarct size. Its mechanism is related to improving myocardial energy metabolism, inhibiting oxidative stress, reducing calcium overload, and anti apoptosis. This provides a direct basis for its use in the study of heart failure after myocardial infarction.
2. Antitumor activity
Recent studies have revealed the potential of CVB-D in the field of oncology. Studies have shown that CVB-D can effectively inhibit the proliferation of many cancer cell lines (such as breast cancer, lung cancer, liver cancer, colon cancer, leukemia, etc.) and induce their apoptosis. Its anti-tumor effect has multiple pathway characteristics:
* Inhibit cell cycle CVB-D can block cancer cells at specific stages of the cell cycle (such as G0/G1 phase or G2/M phase), preventing them from undergoing mitosis.
* Inducing cell apoptosis CVB-D can induce apoptosis mediated by the mitochondrial pathway, manifested as a decrease in mitochondrial membrane potential, release of cytochrome C, activation of Caspase-3/-9, etc.
* Induce autophagy CVB-D has been confirmed to be an autophagy inducer. Autophagy is a double-edged sword that exerts inhibitory effects in the early stages of tumor development and may also promote tumor cell survival in some cases. CVB-D-induced autophagy often synergizes with apoptosis to exert anti-tumor effects.
3. Neurological activity
Due to its high blood-brain barrier penetration, the impact of CVB-D on the central nervous system has begun to receive attention. Preliminary research suggests that it may have a protective effect on cerebral ischemia-reperfusion injury, with mechanisms involving anti-inflammatory and anti apoptotic effects. In addition, its regulatory effect on ion channels may also affect neuronal excitability.
Mechanism of action and molecular targets
The pharmacological effects of CVB-D stem from its precise regulation of multiple key signaling pathways and molecular targets in cells.
1. Core target of cardiovascular action: ion channels
The anti arrhythmic and myocardial electrophysiological effects of CVB-D are mainly achieved through the regulation of multiple ion channels on the myocardial cell membrane. This is highly consistent with the target information provided by the user:
* potassium ion channel CVB-D can suppress fast delayed rectifier potassium current (IKr), and its molecular basis is to inhibit the KCNH2(Encoding hERG protein) and KCNE2 A channel complex composed of (MiRP1). At the same time, it can also suppress slow delayed rectifier potassium currents (IKs), which are caused by KCNQ1 and KCNE1 The protein composition encoded by MinK. In addition, it also has an inhibitory effect on instantaneous outward potassium current (Ito) and other factors. The inhibition of these potassium channels collectively leads to prolonged action potential repolarization (APD).
* Sodium ion channel Voltage gated sodium channels (mainly composed of SCN5A Inhibition of coding can reduce the rate and amplitude of depolarization in myocardial cells at phase 0, slow down conduction, and help eliminate reentry.
* Calcium ion channel Inhibition of L-type calcium channels (mainly caused by CACNA1C Encoding can reduce the influx of calcium ions, help alleviate intracellular calcium overload, and affect the action potential plateau phase.
* Lanine receptor Lanine receptor 2 on the sarcoplasmic reticulum of the myocardium（RYR2）The regulation of calcium may affect the release of intracellular calcium stores and stabilize calcium homeostasis, which is crucial for preventing arrhythmias induced by calcium waves and delayed depolarization (DAD).
Through the synergistic regulation of multiple ion channels, CVB-D can more comprehensively correct abnormal electrical activity, which may be the molecular basis for its significant clinical anti arrhythmic efficacy and relatively small side effects.
2. Core pathways for anti-tumor and cell protective effects: Akt/mTOR and apoptotic network
* Inhibition of Akt/mTOR signaling pathway CVB-D has been clearly reported to attenuate the phosphorylation of Akt (protein kinase B) and its downstream key target mTOR (mammalian rapamycin target protein). The Akt/mTOR pathway is a core pathway that regulates cell growth, proliferation, metabolism, and survival, and is often overactivated in tumors. CVB-D inhibits this pathway, directly leading to reduced protein synthesis, cell cycle arrest, and Induce autophagy The formation of autophagosomes is a common ultrastructural feature of CVB-D treated cells.
* Activate mitochondrial apoptosis pathway CVB-D induces the opening of mitochondrial membrane permeability transition pores (mPTP) or affects Bcl-2 family proteins (such as reducing the Bcl-2/Bax ratio), leading to the breakdown of mitochondrial membrane potential, the release of pro apoptotic factors such as cytochrome C, and the activation of Caspase cascade reaction, ultimately triggering programmed cell death.
* Regulating cell cycle proteins CVB-D can downregulate the expression of cell cycle proteins (such as Cyclin D1, Cyclin B1) and cyclin dependent kinases (CDKs), while upregulating cyclin dependent kinase inhibitors (such as p21, p27), thereby blocking cells at specific cell cycle checkpoints.
3. Other potential mechanisms
The complex network of multifunctional pharmacological effects of CVB-D includes antioxidant (activating Nrf2/HO-1 pathway), anti-inflammatory (inhibiting NF - κ B pathway), and regulation of autophagy apoptosis crosstalk.
Evaluation of drug properties and pharmacokinetics
Based on its physical and chemical properties and preliminary research, CVB-D has shown certain potential as a drug, but there are also challenges.
Drugability assessment：
* Advantage Clear and potent pharmacological activity; Multi targeted effects may bring synergistic therapeutic effects and reduce the risk of drug resistance; Natural product source, novel structure; Preliminary predictions suggest no hERG inhibition or genotoxicity risk, indicating a certain level of safety.
* challenge Poor water solubility may affect its formulation development and oral bioavailability; The blood-brain barrier has high penetrability, and its central side effects need to be evaluated when treating peripheral diseases; As alkaloids, there may be other potential off target effects or toxicity that require comprehensive preclinical safety evaluation.
Pharmacokinetic study：
The pharmacokinetic study of CVB-D is still in depth. Existing animal experiments (mainly in rats) have shown that:
* Absorption and distribution After oral administration, absorption is faster, but absolute bioavailability may not be high due to first pass effects and solubility limitations. It is widely distributed in the body and has a high concentration in blood rich tissues such as the heart, liver, kidneys, and adipose tissue due to its high lipophilicity. Its high BBB penetration has been observed in animal experiments with brain tissue distribution.
* Metabolism and excretion CVB-D is mainly metabolized in the liver, and cytochrome P450 enzyme systems (such as CYP3A4) may be involved in its metabolic process. Metabolites are mostly excreted through bile and urine. Its pharmacokinetic behavior may exhibit characteristics of a two compartment model.
* Improvement in Pharmaceutical Science To improve its bioavailability, researchers are exploring novel drug delivery systems such as liposomes, nanoparticles, solid dispersions, cyclodextrin inclusion complexes, etc. to enhance their solubility and stability.
Clinical application prospects and prospects
The clinical application prospects of Huangyangtao are broad, but it needs to be explored in stages and fields.
1. Cardiovascular disease field (mature and deepening)
* Antiarrhythmic treatment CVB-D, as an effective supplement to existing antiarrhythmic drugs, is particularly suitable for patients who are intolerant to other drugs or have poor efficacy. Future research can focus on precise treatment of specific types of arrhythmias, such as atrial fibrillation and premature ventricular contractions, and conduct more high-quality randomized controlled trials (RCTs) to provide high-level evidence-based medicine.
* heart failure Based on its positive muscle strength without increasing oxygen consumption and clear myocardial protective effect, CVB-D has great potential in the prevention and treatment of chronic heart failure, especially heart failure after myocardial infarction. It is possible to explore its combination with existing standard treatment drugs for heart failure, such as beta blockers, ACEI/ARBs, SGLT2 inhibitors, and observe synergistic effects.
2. The field of tumor treatment (emerging and exploring)
* Adjuvant anti-tumor therapy CVB-D can be used as an adjuvant drug for traditional chemotherapy, radiotherapy, or targeted therapy. Its dual mechanism of inducing autophagy and apoptosis may help overcome tumor drug resistance and eliminate dormant tumor cells. It is necessary to conduct in-depth research on the sensitivity differences of it in different types of tumors and explore its reasonable combination with existing therapies.
* New anti-tumor lead compounds Based on its structure, reasonable chemical modifications are carried out to optimize its activity, selectivity, and pharmacokinetic properties, which is expected to develop new anti-tumor candidate drugs with independent intellectual property rights.
3. Other potential areas
* Protection of the nervous system The protective role in stroke and neurodegenerative diseases is worth exploring preliminarily.
* pulmonary arterial hypertension Its regulation of ion channels and cell proliferation may have an inhibitory effect on vascular remodeling in pulmonary hypertension.
Challenges and Future Directions Faced：
1. Deep exploration of mechanisms By utilizing proteomics, metabolomics, chemical proteomics, and other technologies, the direct target of action is systematically discovered, and a more complete pharmacological toxicological network is drawn.
2. structural optimization Develop derivatives or prodrugs by modifying their structure based on their water solubility and selectivity.
3. Development of a new delivery system Developing targeted formulations using nanotechnology and other technologies to improve therapeutic efficacy and reduce systemic toxicity.
4. Clinical translational research Design and implement rigorous clinical research protocols, especially in the field of new indications such as tumors, starting from phase I clinical trials, gradually verifying their safety and effectiveness.
Conclusion
Cyclovirobuxine D is a modern pharmacological research paradigm derived from the traditional Chinese medicine boxwood. It has evolved from a clinically effective ingredient for treating arrhythmia to a multi-target active molecule that acts on multiple ion channels, regulates the Akt/mTOR core pathway, and affects autophagy and apoptosis. The research process reflects the complete drug development logic from clinical experience to basic research, and then feedback to guide clinical practice and expand new indications. Despite facing challenges such as water solubility in drug development, its clear activity, unique mechanism of action, and good preliminary safety predictions have solidified its position in the field of cardiovascular disease treatment, and it is beginning to emerge in new areas such as anti-tumor therapy. In the future, through interdisciplinary integration, in-depth revelation of its molecular mysteries, and optimization with the help of modern medicinal chemistry and pharmacy methods, boxocarpine is expected to shine with a more brilliant modern medical light from an ancient medicinal plant, contributing new strength to human health.
